{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:28:36Z","timestamp":1792452516288,"version":"4.5.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Macrophage activation syndrome (MAS) is a rare, potentially life-threatening, condition triggered by infections or flares in rheumatologic and neoplastic diseases. The mainstay of treatment includes high dose corticosteroids, intravenous immunoglobulins and immunosuppressive drugs although, more recently, a more targeted approach, based on the use of selective cytokines inhibitors, has been reported. We present the case of a two-year-old boy with 1-month history of high degree fever associated with limping gait, cervical lymphadenopathy and skin rash. Laboratory tests showed elevation of inflammatory markers and ferritin. By exclusion criteria, systemic onset Juvenile Idiopathic Arthritis (sJIA) was diagnosed and steroid therapy started. A couple of weeks later, fever relapsed and laboratory tests were consistent with MAS. He was promptly treated with high doses intravenous methylprednisolone pulses and oral cyclosporin A. One day later, he developed an acute myocarditis and a systemic capillary leak syndrome needing intensive care. Intravenous Immunoglobulin and subcutaneous IL-1-antagonists Anakinra were added. On day 4, after an episode of cardiac arrest, venous-arterial extracorporeal membrane oxygenation (VA-ECMO) was started. Considering the severe refractory clinical picture, we tried high dose intravenous Anakinra (HDIV-ANA, 2 mg\/Kg q6h). This treatment brought immediate benefit: serial echocardiography showed progressive resolution of myocarditis, VA-ECMO was gradually decreased and definitively weaned off in 6 days and MAS laboratory markers improved. Our case underscores the importance of an early aggressive treatment in refractory life-threatening sJIA-related MAS and adds evidence on safety and efficacy of HDIV-ANA particularly in acute myocarditis needing VA-ECMO support.<\/jats:p>","DOI":"10.3389\/fped.2020.635080","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:47:30Z","timestamp":1610930850000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Case Report: Life-Threatening Macrophage Activation Syndrome With Fulminant Myocarditis Successfully Rescued by High Dose Intravenous Anakinra"],"prefix":"10.3389","volume":"8","author":[{"given":"Alessandra","family":"Meneghel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Amigoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pettenazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Padalino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zulian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12969-015-0055-3","article-title":"Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"13","author":"Boom","year":"2015","journal-title":"Pediatric Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/RHU.0b013e318205092d","article-title":"Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids","volume":"17","author":"Bruck","year":"2011","journal-title":"J Clin Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1007\/s10067-018-4095-1","article-title":"Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature","volume":"37","author":"S\u00f6nmez","year":"2018","journal-title":"Clin Rheumatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0167-5273(92)90082-e","article-title":"Symptomatic cardiac involvement in juvenile rheumatoid arthritis","volume":"34","author":"Goldenberg","year":"1992","journal-title":"Int J Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/MD.0000000000006656","article-title":"Refractory adult-onset still disease complicated by macrophage activation syndrome and acute myocarditis. A case report treated with high doses (8mg\/Kg\/d) of anakinra","volume":"96","author":"Parisi","year":"2017","journal-title":"Medicine."},{"key":"B8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jbspin.2010.09.014","article-title":"Adult-onset still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra","volume":"78","author":"Reffeiner","year":"2011","journal-title":"Joint Bone Spine."},{"key":"B9","first-page":"623","article-title":"Anakinra for myocarditis in juvenile idiopathic arthritis","volume":"40","author":"Movva","year":"2013","journal-title":"Tex Heart Inst J."},{"key":"B10","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/rheumatology\/kep418","article-title":"Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis","volume":"49","author":"Vastert","year":"2010","journal-title":"Rheumatology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","article-title":"2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"75","author":"Ravelli","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr2.11135","article-title":"Continuous intravenous Anakinra infusion to calm the cytokine storm in macrophage activation syndrome","volume":"2","author":"Monteagudo","year":"2020","journal-title":"ACR Open Rheumatology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/PCC.0000000000000078","article-title":"Therapeutic role of anakinra, an interleukin-1 receptorantagonist, in the management of secondary hemophagocytic lymphohistiocytosis\/sepsis\/multiple organ dysfunction\/macrophage activating syndrome in critically ill children","volume":"15","author":"Rajasekaran","year":"2014","journal-title":"Pediatr Crit Care Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/cts.12622","article-title":"Pharmacokinetics of anakinra in subjects of heavier vs. lighter body weights","volume":"12","author":"Yang","year":"2019","journal-title":"Clin Transl Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.lpm.2013.06.028","article-title":"Two cases of anakinra-induced neutropenia during autoinflammatory diseases: drug reintroduction can be successful","volume":"43","author":"Perrin","year":"2014","journal-title":"Presse Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/S2352-4642(20)30168-1","article-title":"Acute myocardial injury: a novel clinical pattern in children with COVID-19","volume":"4","author":"Wolfler","year":"2020","journal-title":"Lancet Child Adolesc Health."},{"key":"B19","doi-asserted-by":"publisher","first-page":"102567","DOI":"10.1016\/j.autrev.2020102567","article-title":"Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions","volume":"19","author":"Jamilloux","year":"2020","journal-title":"Autoimmun Rev."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjco.2020.10.003","article-title":"White, rapid response to cytokine storm inhibition using anakinra in a patient with COVID-19 myocarditis","author":"Trpkov","year":"2020","journal-title":"CJC Open"},{"key":"B21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12969-020-00469-y","article-title":"Pediatr Rheumatol","volume":"18","year":"2020"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2020.635080\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:47:32Z","timestamp":1610930852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2020.635080\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":21,"alternative-id":["10.3389\/fped.2020.635080"],"URL":"https:\/\/doi.org\/10.3389\/fped.2020.635080","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,18]]},"article-number":"635080"}}